Practical Strategies for Harnessing AI and Social Media in Dermatology
In her presentation at Fall Clinical NP/PA, Heather Gates, PA-C, shared how professionals can enhance their practice using AI and social media, fostering authenticity and patient trust in a digital age.
Leave the Ladder Down: The Power of Mentoring
Lauren Miller, PA-C, MPAS, highlights the vital role of mentorship in dermatology, emphasizing its impact on professional growth and patient care at the Fall Clinical conference.
Clinical and Conference Insights from a Dermatology PA Leader
Jamie Restivo, PA-C, a board-certified dermatology physician assistant and current president of the Pennsylvania Dermatology Physician Assistants (PDPA), gave insights into the PA perspective.
Interactive Learning Sets Fall Clinical Apart
Explore the latest insights in dermatology at the Fall Clinical PA/NP Conference, featuring experts like James Del Rosso, DO, and networking opportunities for PA NPs.
Fall Clinical PA/NP 2025: Familiar Faces to Dermatology Times
Discover expert insights and practice management tips at the Fall Clinical PA/NP Conference in Orlando, featuring top dermatology professionals.
Road to RAD: Taking Itch Into Consideration
Jonathan Silverberg, MD, PhD, MPH, talks about when and how to take itch into consideration when choosing a therapy for AD.
RAPIDS 2025 Conference Recap: A Thrilling Journey Through Immuno-Dermatology
RAPIDS 2025 captivated with expert insights on immuno-dermatology, featuring engaging sessions and lively panels.
Road to RAD: Lebrikizumab for AD
Jonathan Silverberg, MD, PhD, MPH, shares pearls from the ADvocate1 and 2 trials examining the use of lebrikizumab for AD.
Road to RAD: Nemolizumab for AD
Jonathan Silverberg, MD, PhD, MPH, talks about therapies used for AD, including nemolizumab.
Cutibacterium acnes Dominates the Post-Laser Skin Microbiome
Researchers reveal the resilience of Cutibacterium acnes in the skin microbiome post-laser treatments, suggesting its beneficial roles in skin health and aging.
Triple-Combination Acne Gel Demonstrates Long-Term Safety and Efficacy
A new study highlights the significant long-term improvements in lesions and scarring of a clindamycin phosphate 1.2%, adapalene 0.15%, and benzoyl peroxide 3.1% formulation.
Psoriasis and Cellulitis Burden Has Increased in the US, According to New Posters
Recent posters at SID revealed significant increases in psoriasis and cellulitis cases in the US, highlighting urgent needs for prevention and treatment strategies.
Evidence Highlights Thiamidol’s Efficacy and Safety in Hyperpigmentation Treatment
Thiamidol emerges as a promising treatment for hyperpigmentation, showcasing superior efficacy and safety compared to traditional options like hydroquinone.
GLP-1 Therapy Offers Dual Benefits for Skin and Heart
GLP-1 receptor agonists show promise in reducing cardiovascular risks for patients with chronic inflammatory skin diseases like psoriasis and atopic dermatitis.
IL-23 and IL-17 Inhibitors Reduce Cardiovascular Outcomes in Statin-Treated Psoriasis Patients
Biologics significantly lower cardiovascular risks in psoriasis patients on statins, highlighting their dual benefits for skin and heart health.
Artax Biopharma's AX-158: A Novel Approach to T Cell-Driven Inflammation in Psoriasis
Scott Batty, MD, and Chris VanDeusen, PhD, provided insights on AX-158's phase 2a results, presented at the SID Annual Meeting.
Risankizumab Effective in Difficult-to-Treat Psoriasis Areas
Discover the promising results of risankizumab for treating genital and scalp psoriasis, showcasing significant improvements in symptoms and quality of life.
Recludix Unveils First BTK SH2 Domain Inhibitor
Recludix Pharma unveils a groundbreaking BTK SH2 inhibitor, showcasing superior selectivity and efficacy for chronic spontaneous urticaria treatment at SID 2025.
Prolonged Use of Oral Corticosteroids in Atopic Dermatitis Linked to Increased Cardiovascular Risks
Extended oral corticosteroid therapy in patients with atopic dermatitis significantly increases cardiovascular and thrombotic risks, urging careful treatment evaluations.
Dual Inhibitor TRIV-509 Shows Promise for Rapid Improvement in Atopic Dermatitis
Researchers reveal TRIV-509, a novel monoclonal antibody, shows promise in rapidly improving atopic dermatitis by restoring skin barrier integrity and reducing inflammation.